Ribozymes: Their design and use in cancer

Advances in Experimental Medicine and Biology

Volumn 465, Issue , 2000, Pages 303-318

  Turner, P C ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RIBOZYME; VIRUS VECTOR;

CANCER; DRUG DELIVERY SYSTEM; DRUG STRUCTURE; GENE THERAPY; GLIOMA; HUMAN; INTRON; LEUKEMIA; METASTASIS; MULTIDRUG RESISTANCE; NONHUMAN; ONCOGENE C ERB; ONCOGENE RAS; PRIORITY JOURNAL; PROSTATE CANCER; RETROVIRUS; REVIEW;

ANIMALS; FORECASTING; GENE THERAPY; HUMANS; NEOPLASMS; RNA, CATALYTIC;

UNIDENTIFIED RETROVIRUS;

EID: 0034472822     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (84)

1. The use of DNA viruses as vectors for gene therapy
2. Recent studies of ribonuclease P
3. Molecular cloning and sequence of the gene for p9Ka. A cultured myoepithelial cell protein with strong homology to S-100, a calcium binding protein
4. Secondary structure of the self-cleaving RNA of hepatitis delta virus: Application to catalytic RNA design
5. Triple ribozyme-mediated down-regulation of the retinoblastoma gene
6. Anti-HIV therapeutic hammerhead ribozymes: Targeting strategies and optimization of intracellular function
7. The expression cassette determines the functional activity of ribozymes in mammalian cells by controlling their intracellular localization
8. The structure, function and application of the hammerhead ribozyme
9. Efficient trans cleavage and a common structural motif for the ribozymes of the human hepatitis δ agent
10. Bovine leukaemia virus ribozymes
11. Comparison of the antiviral efficacy of ribozymes and antisense RNA directed against bovine leukemia virus rex/tax
12. Self-splicing of group I introns
13. Potent inhibition of CTLA-4 expression by an anti-CTLA-4 ribozyme
14. A ribozyme specifically suppresses transformation and tumorigenicity of Ha-ras-oncogene-transformed NIH/3T3 cell lines
15. Catalytic cleavage of the androgen receptor messenger RNA and functional inhibition of androgen receptor activity by a hammerhead ribozyme
16. In vitro and in vivo comparison of hammerhead, hairpin and hepatitis delta virus self-processing ribozyme cassettes
17. Melanoma angiogenesis and metastasis modulated by riboenzyme targeting of the secreted growth factor pleiotrophin
18. Ribozyme targeting of the growth factor pleiotrophin
19. Nm23/nucleoside diphosphate kinase: Toward a structural and biochemical understanding of its biological functions
20. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2
21. Development of a hammerhead ribozyme against bcl-2.2. Ribozyme treatment sensitizes hormone-resistant prostate cancer cells to apoptotic agents
22. Development of a hammerhead ribozyme against bcl-2.1. Preliminary evaluation of a potential gene therapeutic agent for hormone-refractory human prostate cancer
23. 2+-binding protein family
24. Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme
25. Crystal structure of a hepatitis delta virus ribozyme
26. Self-cleavage of plus and minus RNAs of a virusoid and a structural model for the active sites
27. Selection of accessible sites for ribozymes on large RNA transcripts
28. Discrimination of a single base change in a ribozyme using the gene for dihydrofolate reductase as a selective marker in Escherichia coli
29. Reversal of cisplatin resistance in vivo by an anti-fos ribozyme
30. Selective reversal of drug resistance in drug-resistant lung adenocarcinoma cells by tumor-specific expression of MDRI ribozyme gene mediated by retrovirus
31. Engineering liposomes for drug delivery: Progress and problems
32. Isolation and characterisation of DNA sequences amplified in multidrug resistant hamster cells
33. The RNA moiety of ribonuclease P is the catalytic subunit of the enzyme
34. RNA catalytic properties of the minimum (-) sTRSV sequence
35. Hairpin catalytic RNA model: Evidence for helices and sequence requirement for substrate RNA
36. Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system
37. Computational approaches to the identification of ribozyme target sites
38. Evaluating and enhancing ribozyme reaction efficiency in mammalian cells
39. HER-2/neu is rate-limiting for ovarian cancer growth - Conditional depletion of HER-2/neu by ribozyme targeting
40. Selection of the best target site for ribozyme-mediated cleavage within a fusion gene for adenovirus E1A-associated 300 kDA protein (p300) and luciferase
41. Ribozyme-mediated reversal of human pancreatic carcinoma phenotype
42. Ribozyme-based gene cleavage approach to chronic arthritis associated with human T cell leukemia virus type I - Induction of apoptosis in synoviocytes by ablation of HTLV-I tax protein
43. Design of RNA enzymes distinguishing a single base mutation in RNA
44. Self-splicing RNA: Autoexcision and autocyclization of the ribosomal RNA intervening sequence of Tetrahymena
45. The molecular biology of hepatitis delta virus
46. Ribozyme-mediated repair of sickle beta-globin mRNAs in erythrocyte precursors
47. Multi-unit ribozyme-mediated cleavage of bcr-abl mRNA in myeloid leukaemias
48. Adenovirus mediated expression of ribozymes in mice
49. Selection of efficient cleavage sites in target RNAs by using a ribozyme expression library
50. Identification of 5′ and 3′ sequences involved in the transcription of the human mdr-1 gene in vivo
51. Reversal of multidrug resistance by a liposome-MDR1 ribozyme complex
52. Reversal of the in vivo metastatic phenotype of human tumor cells by an anti-CAPL (mts-1) ribozyme
53. Ribozymes - Applications in cancer metastasis research
54. Intermolecular cleavage by the newt ribozyme
55. Ribozymes cleave the AML-1/MTG8 fusion transcript and inhibit proliferation of leukaemic cells with t(8;21)
56. Ribozymes targeted against AML-1/MTG8
57. Expression of a p16(INK4a)-specific ribozyme down-modulates p16(INK4a) abundance and accelerates cell proliferation
58. H-ras ribozyme mediated alteration of the human melanoma phenotype
59. Suppression of the malignant phenotype of melanoma cells by anti-oncogene ribozymes
60. A site-specific self-cleavage reaction performed by a novel RNA in Neurospora mitochondria
61. Ribozyme mediated reversal of the multidrug-resistant phenotype
62. Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionine
63. Specific hammerhead ribozyme-mediated cleavage of mutant N-ras mRNA in vitro and ex vivo - Oligoribonucleotides as therapeutic agents
64. Effective reversal of a transformed phenotype by retrovirus-mediated transfer of a ribozyme directed against mutant N-ras
65. Computer-aided calculation of the local folding potential of target RNA and its use for ribozyme design
66. A nuclease-resistant protein kinase C alpha ribozyme blocks glioma cell growth
67. Structural and kinetic characterisation of an acyl transferase ribozyme
68. The use of ribozymes to inhibit HIV replication
69. Anti-c-erb-B-2 ribozyme for breast cancer
70. K-ras ribozyme for lung cancer
71. A small catalytic oligoribonucleotide
72. Recent developments in the hammerhead ribozyme field
73. The hairpin ribozyme: Structure, assembly and catalysis
74. Inhibition of HIV replication by the hairpin ribozyme
75. Selection of a high activity c-erbB-2 ribozyme using a fusion gene of c-erbB-2 and the enhanced green fluorescent protein
76. Ex vivo effects associated with the expression of a bcr-abl-specific ribozyme in a CML cell line
77. Human hepatitis δ virus RNA subfragments contain an autocleavage activity
78. Inhibition of tumor growth by ribozyme-mediated suppression of aberrant epidermal growth factor receptor gene expression
79. Modulation of c-fms proto-oncogene in an ovarian carcinoma cell line by a hammerhead ribozyme
80. Design of hairpin ribozymes for in vitro and cellular applications
81. Application of in vitro selection in design of external guide sequences that direct efficient cleavage of RNA by RNase P
82. Targeted cleavage of RNA using external guide sequences and eukaryotic RNase P
83. Mechanism of oligonucleotide release from cationic liposomes
84. Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype